

Addressing Urgent Needs In Serious Neurologic Disorders

August 2023 • Nasdaq: PXMD

Cautionary Note on Forward-Looking Statements and Disclaimers

This Presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, results of clinical trials and other future conditions. Words such as, but not limited to, "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "plan", "potential", "predict", "project", "should", "will", "would" or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes, identify forward-looking statements.

These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Presentation and are subject to risks and uncertainties. Moreover, the Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for management to predict all risks, nor can the Company assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The Company qualifies all of the forward-looking statements in this Presentation by these cautionary statements. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Although the Company believes that the expectations expressed in these forwardlooking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results described in the Company's "Risk Factors" section and other sections in its most recent Annual Report on Form 10-K, and subsequent quarterly and other filings with the U.S. Securities and Exchange Commission. Statements contained herein are made as of the date of this Presentation unless stated otherwise, and neither this Presentation shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that the information will be updated or revisited to reflect information that subsequently becomes available or changes occurring after that date hereof.

Certain information contained in this Presentation relates to or is based on statistical and other industry and market data obtained from independent industry publications and research, surveys and studies conducted by independent third parties as well as the Company's own estimates. The market data used in this Presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. The Company's estimates of the patient population with the potential to benefit from treatment with any product candidates the Company may develop include several key assumptions based on its industry knowledge, industry publications and third-party research, which may be based on a small sample size and may fail to accurately reflect the addressable patient population. While the Company believes that its internal assumptions are reasonable, no independent source has verified such assumptions.

This Presentation contains trademarks, trade names, or service marks belonging to other entities. The Company does not intend the use or display of other parties' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of, or by these other parties.





Overview

PaxMedica is a clinical stage biopharmaceutical company focused on the development of anti-purinergic drug therapies ("APT") for the treatment of disorders with intractable neurologic symptoms including Autism Spectrum Disorder ("ASD").

PAX-101, an intravenous formulation of suramin, demonstrated a statistically significant and clinically meaningful change on the CGI-I scale in a Phase 2 clinical trial for ASD.

PAX-101 has demonstrated positive topline results in a phase 3 clinical trial for the treatment of Human African Trypanosomiasis (HAT), a rare and fatal tropical disease.

Investment Highlights

PAXMEDICA

- PaxMedica is the only public company focused on developing treatments for the core symptoms of Autism Spectrum Disorder (ASD)
- Currently preparing for a clinical trial of PAX-101 in ASD
- Multiple catalysts expected through 2024
 - Planning a multi-centered clinical trial of PAX-101 in ASD
 - Preparing NDA filing for approval of PAX-101 for the treatment of Human African Trypanosomiasis (HAT), a rare and fatal tropical disease
 - Expect to file in 2024
 - Potential award of U.S. Rare Tropical Disease Priority Review Voucher (PRV)*
- Ample available capital for near-term needs
- Independent Board and management team of experienced industry entrepreneurs



Management Team Led by Experienced Pharma Entrepreneurs





Howard J. Weisman Chief Executive Officer

Stephen Sheldon Chief Operating/Financial Officer



Dr. David Hough Chief Medical Officer



Buzz Woods Corporate Communications

Strong Board of Directors





Zach Rome







Dr. John F. Coelho



Charles J. Casamento

© 2023. PaxMedica, Inc. Proprietary Information. All rights reserved V0816.



PAX-101, PAX-102, Emodin Potential Game-Changing Treatments for Autism



1 in 36 children in the US Is diagnosed with ASD

Autism Spectrum: A Significant Clinical Opportunity

No FDA-approved treatments for Autism core symptoms:


- Deficits in Social Communication
- Restricted and Repetitive Patterns of Behavior
- Significant Impairment in Functioning
- Global Autism treatment market reached \$3.3B in 2018 and is expected to exceed \$4.6 Billion in 2026 (CAGR 4.3%)¹
 - Irritability, a non-core symptom associated with ASD, is treated with available anti-psychotic drugs but tolerability and side effects can be treatment limiting

1. Fortune Business Insights, Autism Spectrum Disorder Therapeutics Market Research Report, August 2019



A New Treatment Pathway Proposed for Autism

PAX-101 may improve symptoms of ASD by blocking the action of ATP on purine receptors that are over-expressed during immune system activation





An Expanding Pipeline of Anti-Purinergic Compounds

Compound	Indication	Pre-Clinical	Phase 1	Phase 2	Phase 3	NDA
PAX-101	Stage 1 Trypanosoma Brucei Rhodesiense Human African Trypanosomiasis					
PAX-101	Autism Spectrum Disorder					
Emodin	Autism Spectrum Disorder					
PAX-102	Autism Spectrum Disorder					




Forging a New Path in ASD Treatment:

PAX-101 Phase 2 Trial in ASD




PAX-101 in ASD Phase 2 Clinical Trial Design



6 sites in Africa – 44 boys completed study – mean age 8.4 years



Primary Endpoint: Aberrant Behavior Checklist (ABC) Positive Individual ABC Subscale Changes




Change from Baseline through Week 14

© 2023. PaxMedica, Inc. Proprietary Information. All rights reserved V0816.



Primary Endpoint: Aberrant Behavior Checklist (ABC) Core Symptoms and Total Symptoms – Positive Change from Baseline over time

PAX-101 Low Dose (10mg/kg) Outperforms Placebo in Core and Total Symptoms Measures



ABC Core Change from Baseline (mean ± SE)


ABC Total Change from Baseline (mean ± SE)



Secondary Endpoint: Clinical Global Impression of Improvement in Overall Severity of Symptoms – Positive Change from Baseline

CGI-I Overall Severity Score, Scaled

Change from Baseline to Week 14 (ITT population, mean ± SE)



Results	Chg from BL	P Value	Adj P Value
10 mg/kg	-2.8 ± 0.30	0.008	0.016
Placebo	-1.7 ± 0.27		





PAX-101: Phase 2 Trial Summary Results

- Both dose regimens showed improvement trends from baseline on ASD core symptoms
- 10 mg/kg dose group showed a statistically significant and clinically meaningful change on the CGI-I
- Confirmation of these results needed in a larger, statistically powered study
- Preparing for next clinical trial of PAX-101 in ASD



PAX-101 for HAT NDA Submission Plans



Filing NDA for HAT in Parallel with ASD Development Work Priority Review Voucher Program for Neglected Tropical Diseases

- IV suramin is the standard of care in the treatment of potentially lethal infections caused by Stage 1 T. Brucei Rhodesiense Human African Trypanosomiasis (HAT), aka African Sleeping Sickness, for over 100 years
- Currently only approved in Africa

PAXMEDICA

- PaxMedica has the exclusive license to suramin-treated patient data from key endemic hospitals
- PAX-101 received FDA Orphan Drug Designation for this neglected tropical disease in Nov. 2020
 - If approved would mean market exclusivity up to seven (7) years
- NDA Sponsors under this program may qualify for FDA benefits, including a Priority Review Voucher. PRV Vouchers can potentially be sold to a third party upon receipt following NDA approval*
- PaxMedica intends to file an NDA for the use of PAX-101 in HAT infections in 2024
 - HAT submission will be a 505(b)(2) NDA
 - If approved, will be the first approval of suramin in the US market

* For full analysis see GAO Report GAO-20-251, as of January 31, 2020

PAX-HAT-301: Registrational Phase 3 Trial in Rare Tropical Disease

Top line Results	 Suramin-treated cohort 114 (94%) survived and completed treatment Natural History cohort 6 (14%) recorded as cured, improved or discharged, 3 (7%) died, 10 (24%) experienced clinical worsening, 17 (40%) achieved moribund status (near death or in terminal decline) The two-sided p-value for the Fisher's exact test was <0.001
Study Design	 Retrospective clinical study to determine efficacy and safety of the use of PAX-101 (suramin) to treat Stage 1 Trypanosoma Brucei Rhodesiense Human African Trypanosomiasis (TBR HAT) 121 in the suramin-treated cohort, 42 in the natural history cohort
Objectives	 Did the suramin treated cohort have better outcomes than those in the Natural History cohort? Any recorded treatment side effects?
Next Steps	 PaxMedica expects Q4 meeting with FDA to discuss updated path to NDA.



Recent Accomplishments Goals and Financials



Recent Accomplishments

PAXMEDICA

- Announced Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301
- Granted Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC
 - First purpose-built limited distribution specialty pharmacy benefit manager that is focused on ASD
 - Establishing initial infrastructure necessary to distribute PAX-101 safely and effectively
- CMC Supply Chain API and Drug Product cGMP Process on track to be completed by year end 2023
- Entered into Research Collaboration Agreement with PoloMar Health and The BRAIN Foundation for Phase II Study in ASD
 - Phase II proof-of-concept trial using a proprietary, highly bioavailable form of emodin in patients with ASD is expected to begin in 2H 2023
 - Positive results were demonstrated in several in vivo animal studies in a mouse model of autism conducted by PaxMedica in 2019



2023-2024 Goals

- Reduce cost of capital and dilution as we approach NDA and potential PRV
- Complete all necessary pre-clinical, non-clinical and clinical studies to support NDA submission for HAT indication
 - Announced Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study
- Fund company through 2025
- Planning for FDA meeting in Q4 2023 for HAT
- Complete manufacturing validation of PAX-101 in preparation for NDA submission in 2024





Ample Capital Available for Near-term Needs

- As of June 30, 2023
 - \$3.1 million in cash on balance sheet
 - Remaining access of approximately \$15.2 million from committed equity investment agreement for up to \$20 million with Lincoln Park Capital
 - 15.4 million shares of Common Stock outstanding
- Potential for award of U.S. Rare Tropical Disease Priority Review Voucher (PRV)



Key Takeaways

- PaxMedica is the only public company focused on developing treatments for the core symptoms of ASD
- Multiple catalysts expected through 2024
 - Planning a multi-centered clinical trial of PAX-101 in ASD
 - Preparing NDA filing for approval of PAX-101 for the treatment of Human African Trypanosomiasis (HAT), a rare and fatal tropical disease
 - Expect to file in 2024
 - Potential award of U.S. Rare Tropical Disease Priority Review Voucher (PRV)
- Ample capital available for near-term needs



THANK YOU!

WWW.PAXMEDICA.COM

For More Information Contact: Buzz Woods PaxMedica Corporate Communications bwoods@paxmedica.com

> Stephanie Prince PCG Advisory sprince@pcgadvisory.com (646) 863-6341